Inhalation Sciences in 3-year research project with 5 organizations, including purchase of new PreciseInhale system by Chiesi
STOCKHOLM, SWEDEN – July 31, 2018. Inhalation Sciences (ISAB) will collaborate in an extensive research project with RCPE (Research Center Pharmaceutical Engineering) in Graz, Austria, the Medical University of Graz, Technical University (Graz) and Italian pharmaceutical company Chiesi. Chiesi has signed a Capital Expenditure Clause for the purchase of a new PreciseInhale system to be used in the project, which has an initial value of 0.9 MSEK.
The research project is titled "Optimization of Biopharmaceutical Toolbox for Inhaled Compounds". It aims to develop new methods and processes in the production of inhaled drugs. It is being led by RCPE. The biggest industrial sponsor is one of Europe's largest and most successful pharmaceutical companies in inhaled medicines, and a long-running customer of ISAB—Chiesi (Chiesi Farmaceutici S.p.A).
Lena Heffler CEO ISAB: "We’re proud and excited that PreciseInhale has been chosen as an essential technological foundation for this new research. Chiesi’s decision to invest in a new PreciseInhale for the project, on top of the one they currently have in their labs, confirms their confidence in the system—and their powerful expertise as leading-edge innovators in inhalation. Our cooperation with all these outstanding research partners will strengthen our profile as we begin commercializing the entire range of PreciseInhale’s capabilities—from preclinical right the way through to clinical development of new inhaled therapies.”
For more information about Inhalation Sciences please contact: Lena Heffler, CEO Email: firstname.lastname@example.org Phone: +46 (0)70 205 96 20Press release in PDF format